** Shares of vaccine maker Novavax NVAX.O fall 6.6% to $6.61 in afternoon trading
** US FDA is asking Novavax to conduct an additional clinical trial for its COVID-19 vaccine, despite previous 90% efficacy results, the Wall Street Journal reports, citing people familiar with the matter
** The request came after appointees under Health Secretary Robert F. Kennedy Jr. intervened in the approval process - WSJ
** Novavax did not immediately respond to a Reuters request for comment
** On Wednesday, NVAX said US FDA asked the company to produce more data on its COVID-19 vaccine if it gets full approval
** Including session's moves, stock down 12.3% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。